Skip to main content
The William Harvey Research Institute - Faculty of Medicine and Dentistry

The 3TR Molecular Pathobiology-Driven Precision Therapy in Early RA study (3TR PARTNER-RA)

[IRAS Project No. 311470] 

Status: In set-up

This study is part of the Taxonomy, Treatments, Targets and Remission (3TR) project which is a large scale public-private initiative that will provide new insights into why medicines are effective or ineffective across 7 different immune-mediated diseases (Chronic obstructive pulmonary disease, Asthma, Crohn’s Disease, Ulcerative Colitis, Multiple Sclerosis, Systemic Lupus Erythematosus, Rheumatoid Arthritis). The project will study over 50,000 patient samples across 50 clinical trials with the aim to improve disease management. There are 69 academic and industry partners participating, covering 15 European countries.

The 3TR PARTNER-RA study aims to test whether RNA signatures (biomarkers), in the tissue which surrounds the joints (synovial tissue) from patients with EARLY Rheumatoid Arthritis (symptoms <12 months) are predictive of response to biologic disease-modifying anti-rheumatic drugs (b-DMARDs)

3TR PARTNER-RA & Data-Resource Metrics

We aim to recruit approximately 200 patients. Synovial tissue, blood, and optional urine, saliva, and stool samples will be collected.

Supported by NIHR Barts Biomedical Research Centre

3TR PARTNER-RA study logo

Back to top